Senolytic market report hype vs what we actually know works
Posted by elle_z in Longevity & Anti-Aging - 1 points, 4 comments.
Came across this Business Research Company forecast, senolytic and anti-aging therapeutics market projected to keep climbing through 2035, driven by demand and all the usual buzzwords. It's basically a market sizing piece, not new science, so worth keeping that in mind.
My take is the headline numbers feel a bit detached from where the research actually sits right now. We have promising human pilot data on a few senolytics like dasatinib plus quercetin, but most of the loud claims are still extrapolated from mouse work and petri dish stuff. Reading market reports that talk about this space like it's already mainstream medicine makes me a little wary, especially when newcomers might think there are proven anti-aging pills on the shelf.
What I keep wondering is whether the bulk of that projected growth is going toward actual senolytic development, or just more supplement branding with "senolytic" slapped on the label 😅 anyone else feel the gap between the market hype and the real evidence is getting wider?
Senolytic market report hype vs what we actually know works
Came across this Business Research Company forecast, senolytic and anti-aging therapeutics market projected to keep climbing through 2035, driven by demand and all the usual buzzwords. It's basically a market sizing piece, not new science, so worth keeping that in mind.
My take is the headline numbers feel a bit detached from where the research actually sits right now. We have promising human pilot data on a few senolytics like dasatinib plus quercetin, but most of the loud claims are still extrapolated from mouse work and petri dish stuff. Reading market reports that talk about this space like it's already mainstream medicine makes me a little wary, especially when newcomers might think there are proven anti-aging pills on the shelf.
What I keep wondering is whether the bulk of that projected growth is going toward actual senolytic development, or just more supplement branding with "senolytic" slapped on the label 😅 anyone else feel the gap between the market hype and the real evidence is getting wider?
Comments
- aspiring_trailrun: You're spot on about the gap, mate. The fish oil problem all over again, where a finding in a dish gets a label and a price tag before any proper human trial shows up. Dasatinib plus quercetin has the most encouraging pilot data I've seen, but "encouraging pilots" and "proven treatment" are still miles apart. The market report framing tends to bundle senolytics with NAD precursors and whatever else is trending, so those headline figures probably include a lot of supplement sales dressed up in s
- former_sauna: True, and that's what frustrates me. The dasatinib/quercetin pilot in idiopathic pulmonary fibrosis patients was interesting, but small and open label, basically a signal at best. Market reports love to flatten that nuance into "senolytic market growing at X% CAGR" because nuance doesn't sell. For what it is worth, I'd want to see replication in larger cohorts before anyone starts calling this a treatment class.
- elle_z: Yeah the IPF pilot is exactly the kind of thing I keep coming back to. It's a signal, not a green light, and I get annoyed watching market pieces present it like we're already there. Replication would change the conversation a lot for me, especially if someone ran a placebo controlled trial with actual functional endpoints and not just biomarker stuff. Without that I stay pretty skeptical that the projected growth maps onto anything clinically real yet.
- elle_z: Yeah exactly, the bundling thing is what gets me. They lump NMN, NR, resveratrol and actual senolytics all into one bucket so the projected number looks way more impressive than any one of those categories deserves 😅 If I had to guess most of that 31B is just supplement branding riding the longevity wave, not real therapeutic development. Would love to know how much is going into actual clinical trials vs marketing tbh.
Community discussion - research and educational context only. Not medical advice.